Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab Plus Modified FOLFIRINOX in Mucinous Ovarian Carcinoma
NCT05665023Phase 2Unknown
- Sponsor
- Yonsei University
- Start
- Oct 2022
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in mucinous ovarian carcinoma (MOC), fallopian tube carcinoma (PFTC) and primary peritoneal carcinoma (PPC), sponsored by Yonsei University. Primary endpoint: Objective Response Rate at 1 year. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
mucinous ovarian carcinoma (MOC)fallopian tube carcinoma (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT05665023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05665023.